The US Food and Drug Administration has tentatively approved the first generic version of lenacapavir, the world’s only twice-yearly injection to prevent HIV, in a step expected to bring the drug within reach in 120 low- and middle-income countries at $40 per person per year. The announcement was made on Monday, November 2, by India’s Dr Reddy’s Laboratories together with Unitaid, the Clinton Health Access Initiative and Wits RHI.
Lenacapavir is a long-acting pre-exposure prophylaxis, or PrEP: medicine taken by an HIV-negative person to avoid getting HIV. Instead of a daily pill, it is injected twice a year. That difference matters because, as Unitaid HIV lead Carmen Pérez Casas put it, people do not always take their daily dose — “and if you do not take it, you cannot get protected against HIV.”
What “tentative approval” actually means
Tentative approval is the FDA’s standard designation for a generic while the originator product remains under patent. It confirms the generic has met the FDA’s scientific and quality requirements, but it does not allow the generic to be sold in the United States, where Gilead Sciences’ originator product, marketed as Yeztugo, remains patent-protected.
What it does allow is purchase by the US government for overseas programmes, and it can speed up regulatory approval in many other countries. The generic is not yet available everywhere in the 120 countries, and countries that require their own approval processes will need to complete those first. Reporting on November 3 also noted that India’s own drug regulator had not yet issued final marketing approval for the generic in India.
$40 against $28,218
The price contrast is the heart of the story. Under a pricing agreement reached in September 2025 between Dr Reddy’s, Unitaid, Wits RHI and the Clinton Health Access Initiative, the generic will cost $40 per person per year in the countries covered by Gilead’s voluntary licensing programme — the same price as daily preventive pills currently available.
Gilead’s originator carries a US list price of $28,218 per year before insurance. The generic therefore does not compete with the originator on price in the United States at all; it is aimed at the 120 countries where the voluntary licence applies, largely in sub-Saharan Africa, Asia and Latin America.
How it happened in 16 months, not a decade
The speed is unusual. Gilead’s originator was approved by the FDA for HIV prevention in June 2025, after large clinical trials showed it was more than 99.9% effective. Just 16 months later, a generic has tentative approval. Unitaid presents that as a break from the usual pattern in which people in lower- and middle-income countries wait a decade or more for breakthrough medicines already available elsewhere.
The path began in October 2024, when Gilead granted royalty-free voluntary licences to six generic manufacturers: Dr Reddy’s, Emcure, Eva Pharma, Ferozsons, Hetero and Mylan. Dr Reddy’s combined the prevention and treatment indications in one application under the FDA’s 505(b)(2) pathway, which allowed a priority review using existing data.
Initial generic supplies are expected to reach some countries before the end of 2026, with broader availability anticipated in 2027. Even before generic availability, more than 125,000 people in 10 early-adopter African countries had already started Gilead’s lenacapavir, according to Unitaid.
What to watch next
Three things will show whether this approval turns into access. First, how quickly national regulators in the 120 countries clear the generic. Second, whether supplies actually arrive before the end of 2026 as the partners expect, and at scale in 2027. Third, whether uptake follows: a twice-yearly injection removes the daily-pill adherence problem, but clinics still need to reach the people most at risk, and demand has previously outstripped supply of the originator in lower- and middle-income countries.
None of those outcomes is guaranteed by a tentative approval, and this article does not claim the drug is already available in all 120 countries. What is now certain is narrower, and still significant: the first generic long-acting HIV prevention injection has cleared the FDA’s quality bar, at a price designed for the countries where HIV prevention is hardest to deliver.
Frequently asked questions
Can the generic be bought in the United States? No. Tentative approval does not permit US sales while Gilead’s originator remains under patent.
Why does twice-yearly matter? Daily PrEP only protects if taken consistently. A twice-yearly injection removes the daily adherence burden, though it still requires clinic visits twice a year.
When will it actually be available? Partners expect first supplies in some countries before the end of 2026, with broader availability in 2027, subject to national approvals.
Sources
Unitaid / Clinton Health Access Initiative announcement, November 2, 2026, via ContagionLive: https://www.contagionlive.com/view/fda-tentatively-approves-first-generic-lenacapavir-prep-for-120-lmics
Clinton Health Access Initiative: https://www.clintonhealthaccess.org/news/us-fda-approves-first-generic-injectable-lenacapavir-for-hiv-prevention/?utm_source=chatgpt.com
Associated Press via MedicalXpress: https://medicalxpress.com/news/2026-11-cheap-generic-breakthrough-hiv-shot.html
The Hindu (AP report): https://www.thehindu.com/sci-tech/health/approval-of-india-made-version-of-hiv-prevention-shot-raises-hopes-in-low-income-countries/article71660754.ece
Business Standard: https://www.business-standard.com/world-news/us-approves-generic-hiv-prevention-drug-lenacapavir-for-poorer-nations-126110201365_1.html
Related on Emadan: US Measles Cases Rise to 4,852, CDC Says 96% Unvaccinated | DR Congo Ebola Death Toll Passes 5,000 in Deadliest Outbreak
